

SmartPA Criteria Proposal

Drug/Drug Class:	Transthyretin-Mediated Amyloidosis (ATTR) Clinical Edit
First Implementation Date:	May 16, 2019
Proposed Date:	September 17, 2020
Prepared for:	MO HealthNet
Prepared by:	MO HealthNet/Conduent
Criteria Status:	<input type="checkbox"/> Existing Criteria <input checked="" type="checkbox"/> Revision of Existing Criteria <input type="checkbox"/> New Criteria

Executive Summary

Purpose: Ensure appropriate utilization and control of agents for transthyretin-mediated amyloidosis (ATTR)

Why Issue Selected: Transthyretin-mediated amyloidosis (ATTR) is a form of systemic amyloidosis caused by amyloid deposits made up of a protein called transthyretin (TTR). ATTR can be either hereditary or acquired (non-hereditary). TTR is always present in the blood, where it transports thyroid hormone and vitamin A (retinol), hence the name: “trans-thy-retin”. When the abnormal proteins are produced and the fibers attach and deposit in organs and other places in the body, normal function of that part of the body is affected. The hereditary form of ATTR is caused by a pathogenic variant in the TTR gene that causes misfolding of the tetramer subunits, while the wild-type form is associated with misfolding of destabilized native protein (particularly in the elderly) and causes non-familial cases. ATTR is a rare disease, affecting < 200,000 people in the US.

Onpattro® (patisiran) and Tegsedi® (inotersen) are indicated for the treatment of the polyneuropathy caused by hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults. These agents work by targeting RNA to reduce the production of the TTR protein thus reducing the accumulation of amyloid deposits in the peripheral nerves, improving symptoms and helping patients better manage the condition. hATTR-PN affects approximately 3,200 people in the United States. The use of Tegsedi requires prescribers and patients to enroll in a Risk Evaluation and Mitigation Strategies (REMS) program due to its potential to cause thrombocytopenia and glomerulonephritis that may require immunosuppressive treatment and may result in dialysis.

Vyndaqel® (tafamidis meglumine) and Vyndamax® (tafamidis) are indicated for the treatment of cardiomyopathy caused by transthyretin-mediated amyloidosis (ATTR-CM) in adults. These agents are for both wild-type transthyretin amyloidosis (ATTRwt) and hereditary transthyretin amyloidosis (hATTR). ATTR-CM results in accumulation of amyloid fibrils in the left ventricle which ultimately causes the myocardium to become stiff, resulting in heart failure. It is estimated that 100,000 people in the US are affected by ATTR-CM. Vyndaqel and Vyndamax are oral TTR stabilizers that selectively bind to TTR, stabilizing the tetramer of the TTR transport protein and slowing the formation of amyloid that causes ATTR-CM.

Due to the high cost, possible adverse events, and specific approved indications, MO HealthNet will impose clinical criteria to ensure appropriate utilization of agents for ATTR.

Program-Specific Information:

Date Range FFS 07/01/2019 to 06/30/2020				
Drug	Claims	Spend	Cost per unit (MAC)	Cost per month (MAC)
ONPATTRO 10MG/5ML VIAL	0	-	\$9,462.00 per vial	\$41,002.00
TEGSEDI 284MG/1.5ML SYR	0	-	\$8,736.50 per syringe	\$34,946.00
VYNDAQEL 20MG CAPSULE	2	\$37,369.10	\$155.62 per capsule	\$18,674.40
VYNDAMAX 61MG CAPSULE	0	-	\$622.50 per capsule	\$18,675.00

- Type of Criteria:** Increased risk of ADE Preferred Drug List
 Appropriate Indications Clinical Edit
- Data Sources:** Only Administrative Databases Databases + Prescriber-Supplied

Setting & Population

- Drug class for review: Agents for transthyretin-mediated amyloidosis (ATTR)
- Age range: All appropriate MO HealthNet participants aged 18 years and older

Approval Criteria

- Participant is aged 18 years or older **AND**
- For documented diagnosis of peripheral nerve disease caused by hATTR:
 - Onpattro or Tegsedi only **AND**
 - Documented transthyretin variant by genotyping **AND**
 - Documented amyloid deposit by biopsy **AND**
 - First claim prescribed by a neurologist or other appropriate specialist in the treated disease state **AND**
 - For Tegsedi:
 - Documentation of laboratory tests prior to treatment, including platelet count, serum creatinine, estimated glomerular filtration rate (eGFR), urine protein to creatinine ratio (UPCR), and urinalysis
 - Limit of 1 syringe (1.5ml) every 7 days
 - Initial approval duration of 6 months in order to reevaluate therapy and ensure proper monitoring has occurred with regards to platelet count, serum creatinine, eGFR, UPCR, and urinalysis as needed. If criteria is met to continue therapy, 6 month renewal PA can be given with re-review required again in 6 months.
- For documented diagnosis of cardiomyopathy caused by ATTR:
 - Vyndaquel **or Vyndamax** only **AND**
 - First claim prescribed by a cardiologist or other appropriate specialist in the treated disease state **AND**
 - Documented amyloid deposit by biopsy or PYP scintigraphy scan **AND**
 - NYHA functional Class I-III **AND**
 - Documented diagnosis of heart failure **or inferred heart failure** **AND**

SmartPA Clinical Proposal Form
 © 2020 Conduent Business Services, LLC. All rights reserved. Conduent™ and Conduent Design™ are trademarks of Conduent Business Services, LLC in the United States and/or other countries.

Other company trademarks are also acknowledged.

- Documented echocardiogram with end-diastolic interventricular septal wall thickness > 12 mm **AND**
- Limit of 120 capsules every 30 days for Vyndaqel **OR**
- **Limit of 30 capsules every 30 days for Vyndamax**
- Initial approval duration of 6 months in order to reevaluate therapy and assessment of efficacy (slowing of clinical decline, decrease in cardiovascular related hospitalizations, improvement in 6-minute walk test, and/or stable or improvement in the Kansas City Cardiomyopathy Questionnaire-Overall Summary (KCCQ-OS)). If criteria is met to continue therapy, 6 month renewal PA can be given with re-review required again in 6 months.

Denial Criteria

- Therapy will be denied if all approval criteria are not met
- For Onpattro or Tegsedi: concurrent therapy with Vyndaqel **or Vyndamax**
- For Vyndaqel **or Vyndamax**:
 - concurrent therapy with Onpattro or Tegsedi **OR**
 - NYHA functional Class IV **OR**
 - ~~GFR < 25 ml per minute per 1.73M² of body surface area~~ **OR**
 - presence of a cardiac mechanical assist device

Required Documentation

Laboratory Results:
 MedWatch Form:

Progress Notes:
 Other:

Disposition of Edit

Denial: Exception "0682" (Clinical Edit)
 Rule Type: CE

Default Approval Period

6 months

References

- Onpattro (patisiran) [prescribing information]. Cambridge, MA: Alnylam Pharmaceuticals, Inc; February 2020.
- Tegsedi (inotersen) [prescribing information]. Carlsbad, CA: Ionis Pharmaceuticals, Inc; October 2019.
- Vyndaqel/Vyndamax [package insert]. New York, NY: Pfizer Labs; April 2020.
- Amyloidosis Foundation. Amyloidosis Facts. <https://amyloidosis.org/facts/>. Accessed July 31, 2020.
- IPD Analytics. New Drug Approval: Onpattro (patisiran). August 2018.
- IPD Analytics. New Drug Approval: Tegsedi (inotersen). October 2018.
- IPD Analytics. New Drug Approval: Vyndamax and Vyndaqel. May 2019.

SmartPA Clinical Proposal Form

© 2020 Conduent Business Services, LLC. All rights reserved. Conduent™ and Conduent Design™ are trademarks of Conduent Business Services, LLC in the United States and/or other countries.

Other company trademarks are also acknowledged.